Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Maternal metabolic health drives mesenchymal stem cell metabolism and infant fat mass at birth
Melissa L. Erickson, Zachary W. Patinkin, Allison M. Duensing, Dana Dabelea, Leanne M. Redman, Kristen E. Boyle
Melissa L. Erickson, Zachary W. Patinkin, Allison M. Duensing, Dana Dabelea, Leanne M. Redman, Kristen E. Boyle
View: Text | PDF
Research Article Metabolism Reproductive biology

Maternal metabolic health drives mesenchymal stem cell metabolism and infant fat mass at birth

  • Text
  • PDF
Abstract

Exposure to maternal obesity may promote metabolic dysfunction in offspring. We used infant mesenchymal stem cells (MSCs) to experimentally examine cellular mechanisms of intergenerational health transmission. Our earlier reports show MSCs collected from infants of mothers with obesity had a dichotomous distribution in metabolic efficiency; they were either efficient (Ef-Ob) or inefficient (In-Ob) with respect to fatty acid oxidation (FAO). Here, we sought to determine if this was due to a primary defect in FAO. Accordingly, we measured FAO in myogenic differentiating MSCs under 3 conditions: (a) myogenesis alone, (b) excess fatty acid exposure, and (c) excess fatty acid exposure plus a chemical uncoupler to increase metabolic rate. Compared with normal weight and Ef-Ob MSCs, In-Ob displayed lower FAO in myogenesis alone and after fatty acid plus uncoupler, indicating In-Ob were less metabolically flexible after increasing lipid availability and metabolic rate, demonstrating a primary deficit in FAO. MSC FAO was negatively associated with fasting maternal glucose and insulin and positively associated with fasting HDL-cholesterol. MSC FAO was negatively associated with infant fat mass. These data indicate a less favorable maternal metabolic milieu, independent of maternal BMI, reduces intrinsic MSC FAO and is linked to higher infant adiposity as early as birth.

Authors

Melissa L. Erickson, Zachary W. Patinkin, Allison M. Duensing, Dana Dabelea, Leanne M. Redman, Kristen E. Boyle

×

Figure 3

Mitochondrial lipid availability is not different between MSC metabolic phenotypes.

Options: View larger image (or click on image) Download as PowerPoint
Mitochondrial lipid availability is not different between MSC metabolic ...
Differences in ASM/CO2 among NW, Ef-Ob, and In-Ob MSC metabolism are not explained by differences total lipid oxidation. (A) Linear fixed effects mixed-model, 2-way ANOVA of total lipid oxidation among MSC metabolic phenotypes (Interaction: F = 1.394; P = 0.255; Condition: F = 9.783, P = 0.0004; Phenotype: F = 2.060; P = 0.149). Post hoc analysis for Condition revealed that the 24hFA condition was elevated compared with both CT and 24hFA+FCCP conditions (P = 0.0002 and P = 0.02, respectively). NW n = 15; Ef-Ob n = 5, In-Ob n = 8. (B) Individual total FAO values shown. Data are presented as means ± SEM. *indicates significant difference from CT and 24hFA+FCCP conditions.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts